

# Paolo Montuschi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/281811/paolo-montuschi-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

120  
papers

7,175  
citations

47  
h-index

83  
g-index

140  
ext. papers

8,190  
ext. citations

6.1  
avg, IF

5.77  
L-index

#	Paper	IF	Citations
120	Sleep Deprivation, Immune Suppression and SARS-CoV-2 Infection.. <i>International Journal of Environmental Research and Public Health</i> , <b>2022</b> , 19,	4.6	3
119	Clinical and transcriptomic features of persistent exacerbation-prone severe asthma in U-BIOPRED cohort.. <i>Clinical and Translational Medicine</i> , <b>2022</b> , 12, e816	5.7	2
118	Dupilumab and tezepelumab in severe refractory asthma: new opportunities. <i>Therapeutic Advances in Chronic Disease</i> , <b>2022</b> , 13, 204062232210973	4.9	2
117	Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation. <i>European Respiratory Journal</i> , <b>2021</b> ,	13.6	1
116	Severe asthma: One disease and multiple definitions. <i>World Allergy Organization Journal</i> , <b>2021</b> , 14, 100606	6	1
115	A multi-omics approach to delineate sputum microbiome-associated asthma inflammatory phenotypes. <i>European Respiratory Journal</i> , <b>2021</b> ,	13.6	1
114	Predictive Markers of Bronchial Hyperreactivity in a Large Cohort of Young Adults With Cough Variant Asthma. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 630334	5.6	1
113	Mapping atopic dermatitis and anti-IL-22 response signatures to type 2-low severe neutrophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> ,	11.5	2
112	Detection and characterisation of extracellular vesicles in exhaled breath condensate and sputum of COPD and severe asthma patients. <i>European Respiratory Journal</i> , <b>2021</b> , 58,	13.6	2
111	Urinary Leukotriene E and Prostaglandin D Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 37-53	10.2	22
110	Exploring the performance of a functionalized CNT-based sensor array for breathomics through clustering and classification algorithms: from gas sensing of selective biomarkers to discrimination of chronic obstructive pulmonary disease.. <i>RSC Advances</i> , <b>2021</b> , 11, 30270-30282	3.7	3
109	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. <i>World Allergy Organization Journal</i> , <b>2021</b> , 14, 100509	5.2	5
108	Medication Adherence in Patients With Severe Asthma Prescribed Oral Corticosteroids in the U-BIOPRED Cohort. <i>Chest</i> , <b>2021</b> , 160, 53-64	5.3	1
107	Development of a Sensing Array for Human Breath Analysis Based on SWCNT Layers Functionalized with Semiconductor Organic Molecules. <i>Advanced Healthcare Materials</i> , <b>2020</b> , 9, e2000377	10.1	22
106	Asthma similarities across ProAR (Brazil) and U-BIOPRED (Europe) adult cohorts of contrasting locations, ethnicity and socioeconomic status. <i>Respiratory Medicine</i> , <b>2020</b> , 161, 105817	4.6	5
105	Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the (). <i>World Allergy Organization Journal</i> , <b>2020</b> , 13, 100464	5.2	11
104	SIRM-SIAAIC consensus, an Italian document on management of patients at risk of hypersensitivity reactions to contrast media. <i>Clinical and Molecular Allergy</i> , <b>2020</b> , 18, 13	3.7	2

103	eNose breath prints as a surrogate biomarker for classifying patients with asthma by atopy. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 146, 1045-1055	11.5	9
102	Exhaled volatile organic compounds as markers for medication use in asthma. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	7
101	NMR-Based Metabolomics for the Assessment of Inhaled Pharmacotherapy in Chronic Obstructive Pulmonary Disease Patients. <i>Journal of Proteome Research</i> , <b>2020</b> , 19, 64-74	5.6	8
100	Stratification of asthma phenotypes by airway proteomic signatures. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 144, 70-82	11.5	28
99	IL-17-high asthma with features of a psoriasis immunophenotype. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 144, 1198-1213	11.5	43
98	Epithelial dysregulation in obese severe asthmatics with gastro-oesophageal reflux. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	4
97	Sputum proteomic signature of gastro-oesophageal reflux in patients with severe asthma. <i>Respiratory Medicine</i> , <b>2019</b> , 150, 66-73	4.6	9
96	Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 577-590	11.5	90
95	Identification and prospective stability of electronic nose (eNose)-derived inflammatory phenotypes in patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 1811-1820.e7	11.5	55
94	Treatable traits in the European U-BIOPRED adult asthma cohorts. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 74, 406-411	9.3	22
93	Impulse oscillometry and nitrogen washout test in the assessment of small airway dysfunction in asthma: Correlation with quantitative computed tomography. <i>Journal of Asthma</i> , <b>2019</b> , 56, 323-331	1.9	5
92	The discovery and development of acclidinium bromide for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Discovery</i> , <b>2018</b> , 13, 563-577	6.2	2
91	Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis. <i>European Respiratory Journal</i> , <b>2018</b> , 51,	13.6	38
90	Comparison of two exhaled biomarkers in children with and without sleep disordered breathing. <i>Sleep Medicine</i> , <b>2018</b> , 45, 83-88	4.6	4
89	Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2018</b> , 12, 1753466618760779	4.9	10
88	Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 258	5.6	22
87	Metabolomic Analysis by Nuclear Magnetic Resonance Spectroscopy as a New Approach to Understanding Inflammation and Monitoring of Pharmacological Therapy in Children and Young Adults With Cystic Fibrosis. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 595	5.6	9
86	Large-Scale Label-Free Quantitative Mapping of the Sputum Proteome. <i>Journal of Proteome Research</i> , <b>2018</b> , 17, 2072-2091	5.6	12

85	U-BIOPRED accessible handprint: combining omics platforms to identify stable asthma subphenotypes <b>2018</b> ,		2
84	Methodological considerations for large-scale breath analysis studies: lessons from the U-BIOPRED severe asthma project. <i>Journal of Breath Research</i> , <b>2018</b> , 13, 016001	3.1	13
83	Lipid phenotyping of lung epithelial lining fluid in healthy human volunteers. <i>Metabolomics</i> , <b>2018</b> , 14, 123	4.7	8
82	Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohort. <i>PLoS ONE</i> , <b>2018</b> , 13, e0203874	3.7	9
81	Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 319-329	5.9	2
80	Dupilumab for the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 357-366	5.9	36
79	A European Respiratory Society technical standard: exhaled biomarkers in lung disease. <i>European Respiratory Journal</i> , <b>2017</b> , 49,	13.6	295
78	The potential role of endothelial dysfunction and platelet activation in the development of thrombotic risk in COPD patients. <i>Expert Review of Hematology</i> , <b>2017</b> , 10, 821-832	2.8	15
77	U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 139, 1797-1807	11.5	163
76	Triple inhaled therapy for chronic obstructive pulmonary disease. <i>Drug Discovery Today</i> , <b>2016</b> , 21, 1820-1887	11.8	25
75	Vilanterol trifenate for the treatment of COPD. <i>Expert Review of Respiratory Medicine</i> , <b>2016</b> , 10, 719-31.8	3.8	11
74	Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers. <i>Journal of Breath Research</i> , <b>2016</b> , 10, 017102	3.1	36
73	Electronic Nose and Exhaled Breath NMR-based Metabolomics Applications in Airways Disease. <i>Current Topics in Medicinal Chemistry</i> , <b>2016</b> , 16, 1610-30	3	53
72	Investigational prostaglandin D2 receptor antagonists for airway inflammation. <i>Expert Opinion on Investigational Drugs</i> , <b>2016</b> , 25, 639-52	5.9	19
71	Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 4131-64	8.3	65
70	Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1308-21	13.6	292
69	Role of beta-blockers in patients with COPD: current perspective. <i>Drug Discovery Today</i> , <b>2015</b> , 20, 129-35.8	5.8	12
68	Comparison of classification methods in breath analysis by electronic nose. <i>Journal of Breath Research</i> , <b>2015</b> , 9, 046002	3.1	57

67	Characteristics of the frequent exacerbator in U-BIOPRED adult severe asthma cohort <b>2015</b> ,		2
66	The Combined Impact of Exhaled Nitric Oxide and Sputum Eosinophils Monitoring in Asthma Treatment: A Prospective Cohort Study. <i>Current Pharmaceutical Design</i> , <b>2015</b> , 21, 4752-62	3.3	17
65	Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. <i>Drug Discovery Today</i> , <b>2014</b> , 19, 1928-35	8.8	50
64	Transcriptional regulation of kinases downstream of the T cell receptor: another immunomodulatory mechanism of glucocorticoids. <i>BMC Pharmacology &amp; Toxicology</i> , <b>2014</b> , 15, 35	2.6	18
63	Nuclear magnetic resonance-based metabolomics discriminates primary ciliary dyskinesia from cystic fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2014</b> , 190, 229-33	10.2	38
62	An investigation on e-nose platform relevance to respiratory diseases <b>2014</b> ,		1
61	High sputum total adiponectin is associated with low odds for asthma. <i>Journal of Asthma</i> , <b>2014</b> , 51, 459-66		10
60	Exhaled nitric oxide as a biomarker in COPD and related comorbidities. <i>BioMed Research International</i> , <b>2014</b> , 2014, 271918	3	62
59	Liquid chromatography-mass spectrometry measurement of leukotrienes in asthma and other respiratory diseases. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2014</b> , 964, 12-25	3.2	32
58	Within-day and between-day repeatability of measurements with an electronic nose in patients with COPD. <i>Journal of Breath Research</i> , <b>2013</b> , 7, 017103	3.1	61
57	The electronic nose in respiratory medicine. <i>Respiration</i> , <b>2013</b> , 85, 72-84	3.7	128
56	Separating smoking-related diseases using NMR-based metabolomics of exhaled breath condensate. <i>Journal of Proteome Research</i> , <b>2013</b> , 12, 1502-11	5.6	73
55	Application of Omics technologies to biomarker discovery in inflammatory lung diseases. <i>European Respiratory Journal</i> , <b>2013</b> , 42, 802-25	13.6	174
54	Measurement of Biomarkers of Oxidative Stress and Airway Inflammation in Exhaled Breath Condensate: Methodology and Potential Applications in Patients with COPD and Healthy Smokers <b>2013</b> , 360-381		3
53	Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. <i>Current Medicinal Chemistry</i> , <b>2013</b> , 20, 1477-95	4.3	50
52	Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD. <i>Current Medicinal Chemistry</i> , <b>2013</b> , 20, 1464-76	4.3	39
51	NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosis. <i>Thorax</i> , <b>2012</b> , 67, 222-8	7.3	121
50	Exhaled nitric oxide measurement in patients affected by nasal polyposis. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2012</b> , 147, 351-6	5.5	16

49	Pharmacotherapy of patients with mild persistent asthma: strategies and unresolved issues. <i>Frontiers in Pharmacology</i> , <b>2011</b> , 2, 35	5.6	14
48	New perspectives in pharmacological treatment of mild persistent asthma. <i>Drug Discovery Today</i> , <b>2011</b> , 16, 1084-91	8.8	50
47	Exhaled Breath Condensate Biomarkers of Airway Inflammation and Oxidative Stress in COPD <b>2011</b> , 421-440		
46	Toward a personalized pharmacotherapy of respiratory diseases. <i>Frontiers in Pharmacology</i> , <b>2010</b> , 1, 131	5.6	12
45	Role of Leukotrienes and Leukotriene Modifiers in Asthma. <i>Pharmaceuticals</i> , <b>2010</b> , 3, 1792-1811	5.2	30
44	Diagnostic performance of an electronic nose, fractional exhaled nitric oxide, and lung function testing in asthma. <i>Chest</i> , <b>2010</b> , 137, 790-6	5.3	162
43	Measurement of 8-isoprostane in exhaled breath condensate. <i>Methods in Molecular Biology</i> , <b>2010</b> , 594, 73-84	1.4	27
42	8-Isoprostane in exhaled breath condensate and exercise-induced bronchoconstriction in asthmatic children and adolescents. <i>Chest</i> , <b>2009</b> , 135, 66-73	5.3	88
41	Pharmacotherapy of asthma: regular treatment or on demand?. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2009</b> , 3, 175-91	4.9	4
40	LC/MS/MS analysis of leukotriene B4 and other eicosanoids in exhaled breath condensate for assessing lung inflammation. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2009</b> , 877, 1272-80	3.2	78
39	Acute Effects of Air Pollution on Pulmonary Function, Airway Inflammation, and Oxidative Stress in Asthmatic Children. <i>Environmental Health Perspectives</i> , <b>2009</b> , 117, 668-674	8.4	175
38	Acute effects of air pollution on pulmonary function, airway inflammation, and oxidative stress in asthmatic children. <i>Environmental Health Perspectives</i> , <b>2009</b> , 117, 668-74	8.4	130
37	Exhaled 8-isoprostane and prostaglandin E(2) in patients with stable and unstable cystic fibrosis. <i>Free Radical Biology and Medicine</i> , <b>2008</b> , 45, 913-9	7.8	69
36	Chronic obstructive pulmonary disease phenotyping: a possible role for 8-isoprostane measurement in exhaled breath condensate?. <i>Respiration</i> , <b>2008</b> , 75, 134-5	3.7	4
35	Leukotrienes, antileukotrienes and asthma. <i>Mini-Reviews in Medicinal Chemistry</i> , <b>2008</b> , 8, 647-56	3.2	58
34	Analysis of exhaled breath condensate in respiratory medicine: methodological aspects and potential clinical applications. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2007</b> , 1, 5-23	4.9	127
33	Pharmacological modulation of the leukotriene pathway in allergic airway disease. <i>Drug Discovery Today</i> , <b>2007</b> , 12, 404-12	8.8	70
32	Insights into oxidative stress: the isoprostanes. <i>Current Medicinal Chemistry</i> , <b>2007</b> , 14, 703-17	4.3	198

31	Effects of montelukast treatment and withdrawal on fractional exhaled nitric oxide and lung function in children with asthma. <i>Chest</i> , <b>2007</b> , 132, 1876-81	5.3	64
30	Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2006</b> , 118, 347-53	11.5	72
29	Isoprostanes and asthma. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2006</b> , 3, 287-292		8
28	Pharmacological treatment of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , <b>2006</b> , 1, 409-23	3	28
27	Exhaled breath condensate analysis in patients with COPD. <i>Clinica Chimica Acta</i> , <b>2005</b> , 356, 22-34	6.2	77
26	Liquid chromatography/mass spectrometry analysis of exhaled leukotriene B4 in asthmatic children. <i>Respiratory Research</i> , <b>2005</b> , 6, 119	7.3	55
25	Inflammatory response to sputum induction measured by exhaled markers. <i>Respiration</i> , <b>2005</b> , 72, 594-9	3.7	17
24	Ion trap liquid chromatography/tandem mass spectrometry analysis of leukotriene B4 in exhaled breath condensate. <i>Rapid Communications in Mass Spectrometry</i> , <b>2004</b> , 18, 2723-9	2.2	53
23	Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children. <i>Journal of Allergy and Clinical Immunology</i> , <b>2004</b> , 114, 761-7	11.5	105
22	Isoprostanes: markers and mediators of oxidative stress. <i>FASEB Journal</i> , <b>2004</b> , 18, 1791-800	0.9	553
21	Increased exhaled 8-isoprostane in childhood asthma. <i>Chest</i> , <b>2003</b> , 124, 25-31	5.3	114
20	Ozone-induced increase in exhaled 8-isoprostane in healthy subjects is resistant to inhaled budesonide. <i>Free Radical Biology and Medicine</i> , <b>2002</b> , 33, 1403-8	7.8	51
19	Indirect monitoring of lung inflammation. <i>Nature Reviews Drug Discovery</i> , <b>2002</b> , 1, 238-42	64.1	60
18	Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2002</b> , 166, 301-6	10.2	164
17	Diagnosing nonimmediate reactions to penicillins by in vivo tests. <i>International Archives of Allergy and Immunology</i> , <b>2002</b> , 129, 169-74	3.7	93
16	Exhaled leukotrienes and prostaglandins in asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2002</b> , 109, 615-20	11.5	185
15	Analysis of exhaled breath condensate for monitoring airway inflammation. <i>Trends in Pharmacological Sciences</i> , <b>2002</b> , 23, 232-7	13.2	152
14	Exhaled carbon monoxide and nitric oxide in COPD. <i>Chest</i> , <b>2001</b> , 120, 496-501	5.3	130



13	Increased nitrosothiols in exhaled breath condensate in inflammatory airway diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2001</b> , 163, 854-8	10.2	170
12	Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2000</b> , 162, 1175-7	10.2	454
11	Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>1999</b> , 160, 216-20	10.2	444
10	Anaphylaxis increases 8-iso-prostaglandin F2alpha release from guinea-pig lung in vitro. <i>European Journal of Pharmacology</i> , <b>1999</b> , 365, 59-64	5.3	52
9	8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>1998</b> , 158, 1524-7	10.2	211
8	Tachykinin NK2 receptor antagonists decrease eicosanoid release in lung anaphylaxis. <i>European Journal of Pharmacology</i> , <b>1996</b> , 313, R1-3	5.3	3
7	In vitro testing for lung toxicity: a method for distinguishing between immune- and non-immune-mediated reactions to xenobiotics. <i>Environmental Toxicology and Pharmacology</i> , <b>1996</b> , 2, 201-5	5.8	1
6	Gallbladder emptying, plasma levels of estradiol and progesterone, and cholecystokinin secretion in liver cirrhosis. <i>Digestive Diseases and Sciences</i> , <b>1995</b> , 40, 428-34	4	23
5	Blood levels of vasoactive intestinal polypeptide in normal and growth retarded fetuses: relationship with acid-base and haemodynamic status. <i>Early Human Development</i> , <b>1995</b> , 41, 69-77	2.2	5
4	Interleukin-1 receptor antagonist displays intrinsic agonist activity on rat gastric fundus motility in vitro. <i>European Journal of Pharmacology</i> , <b>1995</b> , 275, 31-7	5.3	3
3	Evidence that interleukin-1 beta and tumor necrosis factor inhibit gastric fundus motility via the 5-lipoxygenase pathway. <i>European Journal of Pharmacology</i> , <b>1994</b> , 252, 253-60	5.3	20
2	Interleukin-1 alpha and tumour necrosis factor inhibit rat gastric fundus motility in vitro. <i>European Journal of Pharmacology</i> , <b>1993</b> , 233, 303-4	5.3	14
1	Effects of vasoactive intestinal polypeptide on antigen-induced bronchoconstriction and thromboxane release in guinea-pig lung. <i>British Journal of Pharmacology</i> , <b>1993</b> , 109, 243-50	8.6	14